Ardent Health (NYSE:ARDT – Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 0.900-1.270 for the period, compared to the consensus EPS estimate of 1.120. The company issued revenue guidance of $6.4 billion-$6.7 billion, compared to the consensus revenue estimate of $6.6 billion.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on the company. Royal Bank Of Canada decreased their price target on Ardent Health from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Monday, March 9th. JPMorgan Chase & Co. decreased their price target on Ardent Health from $12.00 to $11.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 20th. Leerink Partners decreased their price target on Ardent Health from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday, March 6th. Finally, Zacks Research raised Ardent Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, March 25th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Ardent Health currently has an average rating of “Hold” and a consensus price target of $14.25.
View Our Latest Report on Ardent Health
Ardent Health Price Performance
Ardent Health (NYSE:ARDT – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.10. Ardent Health had a return on equity of 14.30% and a net margin of 2.15%.Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. On average, research analysts forecast that Ardent Health will post 1.11 earnings per share for the current year.
Institutional Investors Weigh In On Ardent Health
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Goldentree Asset Management LP raised its position in shares of Ardent Health by 99.7% in the fourth quarter. Goldentree Asset Management LP now owns 2,303,113 shares of the company’s stock valued at $20,302,000 after buying an additional 1,150,000 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Ardent Health by 1,684.9% during the first quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company’s stock worth $10,558,000 after acquiring an additional 724,841 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Ardent Health by 75.6% during the second quarter. Ameriprise Financial Inc. now owns 1,634,822 shares of the company’s stock worth $22,332,000 after acquiring an additional 703,739 shares during the last quarter. Bridgeway Capital Management LLC grew its stake in Ardent Health by 108.2% in the 4th quarter. Bridgeway Capital Management LLC now owns 946,571 shares of the company’s stock worth $8,358,000 after acquiring an additional 491,961 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC purchased a new stake in Ardent Health in the 3rd quarter worth approximately $6,377,000.
About Ardent Health
Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.
Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.
Read More
Receive News & Ratings for Ardent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardent Health and related companies with MarketBeat.com's FREE daily email newsletter.
